Science Explorer Interactive view Map
Company · Copenhagen · Denmark

Genmab (Denmark)

Research works
34
◆ 0% vs 2013–17
Citations
1.2k
34.4 per fractional work
Top-10% rate
22.8%
record average 16.5%
Open access
50%
world 28%

Not ranked overall: Genmab (Denmark) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 0.87× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 2.58× its world share, 0 worksImmunology and Micro…Neuroscience: 0.31× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 1.73× its world share, 0 worksPharmacology, Toxico…Mathematics: 0.22× its world share, 0 worksMathematicsHealth Professions: 0.10× its world share, 0 worksHealth ProfessionsMedicine: 4.66× its world share, 9 worksMedicineEconomics, Econometrics and Finance: 0.74× its world share, 0 worksEconomics, Econometr…world share
more than its size predictsabout as predictedless

Rings at 0.5×, and 2×. Widest outward: Medicine, 4.7×. Every wedge is a field page.

Which keywords describe research at Genmab (Denmark)?

By fractional works in all years, weighted toward what it does more of than the world: Lymphoma, Rituximab, PET Imaging, Classification, Molecular Profiling, Prognostic Factors, Chemotherapy and Monoclonal Antibodies.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 33 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 33 words, with their numbers
  1. Lymphoma7▲ 139×3 topics
  2. Rituximab7▲ 129×3 topics
  3. PET Imaging5▲ 74×4 topics
  4. Classification4▲ 35×1 topic
  5. Molecular Profiling4▲ 108×1 topic
  6. Prognostic Factors4▲ 24×6 topics
  7. Chemotherapy3▲ 14×13 topics
  8. Monoclonal Antibodies3▲ 67×2 topics
  9. Cancer Immunotherapy3▲ 68×3 topics
  10. Therapeutic Targets3▲ 39×2 topics
  11. Glycosylation3▲ 40×2 topics
  12. Immunotherapy3▲ 14×7 topics
  13. CAR T Cells3▲ 182×1 topic
  14. Chimeric Antigen Receptor3▲ 182×1 topic
  15. Fc Receptors3▲ 81×1 topic
  16. Leukemia3▲ 122×2 topics
  17. Therapeutic Antibodies3▲ 63×1 topic
  18. Tumor Regression3▲ 92×2 topics
  19. Chronic Lymphocytic Leukemia3▲ 156×1 topic
  20. Genomic Aberrations3▲ 156×1 topic
  21. Breast Cancer2▲ 17×2 topics
  22. Epidemiology2▲ 1.26×12 topics
  23. Trastuzumab2▲ 118×2 topics
  24. EGFR2▲ 153×1 topic
  25. HER22▲ 153×1 topic
  26. Tumor Microenvironment2▲ 12×4 topics
  27. Angiogenesis1▲ 10×4 topics
  28. Inflammation1▲ 1.70×9 topics
  29. Minimal Residual Disease1▲ 55×2 topics
  30. Contact Allergy1▲ 103×1 topic
  31. Skin Sensitization1▲ 103×1 topic
  32. Staging System1▲ 49×2 topics
  33. Targeted Therapy1▲ 14×4 topics

Which research topics does Genmab (Denmark) publish most on?

By volume in 2022–2025: Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research and Monoclonal and Polyclonal Antibodies Research.

  1. 1 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 3 works
  2. 2 CAR-T cell therapy research Oncology 2 works
  3. 3 Chronic Lymphocytic Leukemia Research Genetics 1 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  5. 5 Cancer Immunotherapy and Biomarkers Oncology 0 works
  6. 6 HER2/EGFR in Cancer Research Oncology 0 works
  7. 7 Biosimilars and Bioanalytical Methods Immunology 0 works
  8. 8 Cutaneous lymphoproliferative disorders research Dermatology 0 works
  9. 9 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 0 works
  10. 10 Economic and Financial Impacts of Cancer Economics and Econometrics 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available50.0%not open50.0%

World: 28% of research is openly available.

with international co-authors80.9%domestic only19.1%

World: 19% is written across borders.

How has Genmab (Denmark)'s research output changed?

Output in 2018–2022 was 0% lower than in 2013–2017.

2005201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Copenhagen

All research institutions in Copenhagen

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.